Apnimed has only traded publicly for a few weeks, but Bank of America already sees meaningful upside as the biotech moves closer to a potentially important FDA decision on its experimental sleep apnea pill.
Apnimed (APMD) began trading on Nasdaq on July 31 after pricing an upsized initial public offering at $16 per share. The company sold 13.8 million shares, including the underwriters’ full exercise of their option, raising $220.8 million in gross proceeds. BofA Securities was one of the joint book-running managers on the offering.
Bank of America said in a note given to TheStreet that it initiated coverage of Apnimed with a Buy rating and a $41 price objective. The target represented roughly 60% upside from the $25.63 reference price used in the Aug. 25 note.
The bank’s thesis centers on Oxnimbi, also known as AD109, Apnimed’s lead and sole clinical product candidate.
BofA believes the oral therapy could offer a differentiated approach to obstructive sleep apnea (OSA), supported by positive Phase 3 data and a large population of diagnosed patients who remain untreated.
BofA sees Apnimed’s Oxnimbi filling gap in sleep apnea treatment
Sleep apnea treatment has historically been dominated by positive airway pressure devices such as CPAP, which can be highly effective when patients use them consistently. BofA argues that adherence remains a major weakness in the market and creates room for an oral alternative.
Oxnimbi is designed to target upper-airway neuromuscular dysfunction during sleep. That gives the drug a different mechanism from CPAP and from Eli Lilly’s Zepbound, which became the first FDA-approved medication for OSA in December 2024. Zepbound’s sleep apnea indication is limited to adults with obesity and moderate-to-severe disease.
More Medical Stocks
- 135-year-old healthcare giant surges on cancer vaccine breakthrough
- UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
- Healthcare giant slashes key consultation fee to beat rivals
BofA sees that distinction as important because Oxnimbi was studied across mild, moderate, and severe OSA and in patients with and without obesity.
Apnimed reported that its SynAIRgy Phase 3 trial produced a 55.6% reduction in apnea-hypopnea index under the on-treatment analysis, while also showing significant improvements in oxygenation.
The market opportunity could also be sizable. Apnimed has estimated that approximately 10.5 million people in the U.S. have been diagnosed with OSA but are not receiving treatment. Its SEC prospectus says the company plans to focus an initial Oxnimbi launch on that group if the drug wins approval.
BofA models about $2 billion in nominal peak U.S. sales for Oxnimbi and roughly $1.7 billion on a risk-adjusted basis. Its valuation assumes an 85% probability of success, 30% peak pharmacotherapy penetration, and an 8% share for Oxnimbi within the drug-treated market.
FDA decision is Apnimed’s next major test
The FDA accepted Apnimed’s new drug application for AD109 in July and assigned a Feb. 28, 2027, target action date. The application is supported by the SynAIRgy and LunAIRo Phase 3 trials, both of which met their primary endpoints and showed statistically significant reductions in apnea-hypopnea index.
Approval would give Apnimed a chance to establish a new oral treatment category, but BofA still sees questions around tolerability and how quickly doctors would adopt the drug.
Patient-reported outcomes were mixed across the full Phase 3 population, according to BofA, although a prespecified symptomatic subgroup produced stronger results. The bank also pointed to a roughly 25% pooled discontinuation rate, with insomnia among the tolerability issues drawing attention.
Those issues could shape the commercial ramp, even if the FDA approves the drug. BofA lists slower-than-expected uptake, a narrower-than-expected label, and potential future cash raises among the downside risks to its price target.
For now, the bank is betting the treatment gap is large enough to outweigh those concerns. With an FDA decision scheduled for early 2027, Apnimed has a clear catalyst that could determine whether BofA’s bullish forecast starts to take shape.
Related: Analyst warns Inspire Medical has a problem lasting into 2028
